Reliable Data You Can Trust
Reliable Data You Can Trust
A recent report ongoing study by Infinium Global Research on the cancer stem cell therapy market provides an in-depth analysis of segments and sub-segments in the global as well as regional cancer stem cell therapy market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional cancer stem cell therapy market over the short term as well as the long term. The report is a comprehensive presentation of trends, forecasts, and dollar values of the global cancer stem cell therapy market. According to the report, the global cancer stem cell therapy market is projected to grow at a significant CAGR over the forecast period of 2021-2027.
A discount population of cells that exhibit distinctive self-renewal, proliferation, and differentiation capabilities, are known as cancer stem cells (CSCs) or cancer-initiating cells. Such discount population cells are believed to play a critical role in cancer initiation, maintenance, progression, drug resistance, and cancer recurrence or metastasis. For identifying and enriching CSCs, various cell surface markers like CD44, CD24, and CD133 are used. While, the CSCs properties are controlled by a regulatory network consisting of microRNAs, Notch, and Hedgehog signaling pathways. Furthermore, emerging clinical evidence proves that CSCs are resistant to conventional radiation treatment and chemotherapy. Moreover, CSCs are an essential target for novel anti-cancer drug discovery development of specific therapies. Such therapies targeted at CSCs hold hope for improving cancer patients' survival and quality of life, especially for patients with metastatic disease. Additionally, many major players in cancer stem cells are investing money and funding associated R&D activity to get a breakthrough for cancer treatment due to the rising fatality rate of cancer globally.
Some of the prime factors propelling the growth of the cancer stem cell therapy market are the pouring of funds into R&D activities and government initiatives to boost research related to cancer, successful ventures in clinical oncology, the improved survival rate of patients, and an increase in transplantation procedures. Furthermore, due to the rise in the prevalence of cancer, an increasing number of cancer patients have been seen. Cancer Research UK stated that around 17 million cancer cases were registered in 2018, out of which 56% were fatal. Because of this reason, there is a rising demand for cancer stem cell therapy, which is boosting the growth of the market. Moreover, many technological advancements are ongoing in cancer stem cells which is likely to drive the cancer stem cell therapy market during the forecast period. However, the diagnosis and expensive cell therapy treatments through stem cell treatment contain many inequality issues, significantly hampering the growth of the cancer stem cell therapy market. Moreover, high-cost cell therapies and stringent regulations are other primary factors inhibiting the development of the market.
North America is expected to dominate the cancer stem cell therapy market by holding the largest revenue share during the forecast period. Many favorable government initiatives are supporting the market’s growth in the region. For instance, a new research funding of USD 6 million to accelerate stem cell-based therapies for type 1 diabetes was announced by Canada and JDRF Canada in November 2020. Additionally, the technological advancement in regenerative medicine is expected to support the market’s growth in the region. Furthermore, in Europe, Turkey is emerging as a hotspot for stem cells, a fast-growing medical practice owing to factors such as hospitality, modern laboratory equipment, and ‘‘high-quality, low-cost stem cell treatment’’, creating a lucrative market for stem cell investors. Also, the government of the European region is heavily investing in cancer treatment and related research, which will boost the growth of the cancer stem cell treatment market in the area.
The report on the global cancer stem cell therapy market covers segments such as type, therapeutic area, and end-user. On the basis of type, the sub-markets include allogeneic stem cell therapy, and autologous stem cell therapy. On the basis of therapeutic areas, the sub-markets include oncology, orthopedics, cardiovascular disease, neurology, and others. On the basis of end-user, the sub-markets include hospitals, clinics, and others.
The report provides profiles of the companies in the market such as Astellas Pharma Inc., Novadip Biosciences, MEDIPOST, Fujifilm Cellular Dynamics, DiscGenics, Mesoblast Ltd., and Takeda Pharmaceutical.
The report provides deep insights
into the demand forecasts, market trends, and micro and macro indicators. In
addition, this report provides insights into the factors that are driving and
restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis
given in the report brings an insight into the investment areas that existing
or new market players can consider. The report provides insights into the
market using analytical tools such as Porter's five forces analysis and DRO
analysis of the cancer stem cell therapy market. Moreover, the study highlights
current market trends and provides forecasts from 2021-2027. We also have
highlighted future trends in the market that will affect the demand during the
forecast period. Moreover, the competitive analysis given in each regional
market brings an insight into the market share of the leading players.
Please Choose One of them.